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Abstract
Rheumatoid arthritis (RA) is characterized by the recruitment of
leukocytes and the accumulation of inflammatory mediators
within the synovial compartment. Release of the chemokine
CCL18 has been widely attributed to antigen-presenting cells,
including macrophages and dendritic cells. This study
investigates the production of CCL18 in polymorphonuclear
neutrophils (PMN), the predominant cell type recruited into
synovial fluid (SF). Microarray analysis, semiquantitative and
quantitative reverse transcriptase polymerase chain reaction
identified SF PMN from patients with RA as a novel source for
CCL18 in diseased joints. Highly upregulated expression of
other chemokine genes was observed for CCL3, CXCL8 and
CXCL10, whereas CCL21 was downregulated. The chemokine
receptor genes were differentially expressed, with upregulation
of CXCR4, CCRL2 and CCR5 and downregulation of CXCR1
and CXCR2. In cell culture experiments, expression of CCL18
mRNA in blood PMN was induced by tumor necrosis factor α,
whereas synthesis of CCL18 protein required additional
stimulation with a combination of IL-10 and vitamin D3. In
comparison, recruited SF PMN from patients with RA were
sensitized for CCL18 production, because IL-10 alone was
sufficient to induce CCL18 release. These results suggest a
release of the T cell-attracting CCL18 by PMN when recruited
to diseased joints. However, its production is tightly regulated at
the levels of mRNA expression and protein synthesis.
Introduction
Polymorphonuclear neutrophils (PMN) are effector cells dur-
ing inflammation, and their migration to sites of infection is
essential in controlling microbial growth and dissemination
[1,2]. Neutrophilic infiltration has, however, also been impli-
cated in the pathology of various acute and chronic inflamma-
tory diseases, such as rheumatoid arthritis (RA), gouty arthritis
and Crohn's disease [3-5]. In RA, PMN are highly abundant in
synovial fluid (SF) during acute flares of the disease [6]. In
addition, PMN have been detected at the pannus–cartilage
junction at sites of erosion, suggesting that they contribute to
cartilage destruction through the release of their proteolytic
contents [7,8]. Moreover, PMN obtained from SF from
patients with RA were found to produce a number of cytokines
and chemotactic factors involved in the recruitment of inflam-
matory cells [9,10]. Because PMN are among the first cells to
arrive at an inflammatory site, these observations raise the pos-
sibility that SF PMN may be able to perpetuate the inflamma-
tory process through the release of inflammatory mediators
such as cytokines and chemokines.
APC = allophycocyanin; DC = dendritic cell; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immunosorbent assay; FCS = 
fetal calf serum; IL = interleukin; PBMC = peripheral blood mononuclear cells; PBS = phosphate-buffered saline; PMN = polymorphonuclear neu-
trophils; RA = rheumatoid arthritis; RT-PCR = reverse transcriptase polymerase chain reaction; SF = synovial fluid; TNF = tumor necrosis factor.Arthritis Research & Therapy    Vol 9 No 5    Auer et al.
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Chemokines are a superfamily of more than 50 different chem-
otactic proteins participating in the cellular traffic of immune
and inflammatory responses [11]. They are categorized into at
least four subfamilies, namely C, CC, CXC and CX3C, distin-
guished by the presence or absence of a residue (X) between
two conserved cysteine residues in the N terminus. Chemok-
ines range in size from 8 to 10 kDa and are produced by a
wide variety of cell types [10,12]. Their production either
occurs constitutively or may be induced by appropriate stimu-
lation with exogenous or endogenous agents, such as the
proinflammatory cytokines IL-1 and TNF-α [13]. Chemokines
are known to exert their biological effects on various cell types
through binding to G-protein-coupled cell surface receptors
with seven transmembrane domains [14]. Chemokine recep-
tors may be specific for one ligand or they may bind several
chemokines [15], thus allowing redundancy of the system.
During activation of PMN, expression of CC chemokine recep-
tors is upregulated, whereas that of some CXC receptors is
downregulated [16]. Regulation of chemokine activities there-
fore occurs at the levels of receptor expression as well as lig-
and production.
CCL18, also named pulmonary and activation-regulated
chemokine (PARC), dendritic cell-derived CC chemokine-1
(DC-CK1), alternative macrophage activation-associated CC
chemokine-1 (AMAC-1) and macrophage inflammatory pro-
tein-4 (MIP-4), has been described to attract naïve T cells and
mantle-zone B cells [17]. Cellular sources of CCL18 are pri-
marily monocytes/macrophages and dendritic cells (DCs). Its
production occurs constitutively but may be increased by
additional stimulation with cytokines such as IL-10 and IL-4 as
well as vitamin D3 [18,19]. In RA, expression of mRNA encod-
ing CCL18 was observed in synovial tissue and it coincided
with CCL18 accumulation in SF [19,20].
The present study used a broad-scale experimental approach,
involving microarray and quantitative RT-PCR analyses, to
determine whether PMN can serve as a site for CCL18 pro-
duction in RA. The results demonstrate that SF PMN from
patients with RA are a cellular source for CCL18, the produc-
tion of which is differentially regulated at the levels of mRNA
expression and protein synthesis. Moreover, because PMN
are recruited into SF, a characteristic chemokine expression
profile is induced with highly upregulated mRNAs for CCL3,
CCL18, CXCL8 and CXCL10 and downregulation of CCL21
mRNA.
Materials and methods
Patients
SF samples were taken from knees of nine patients with active
RA, for treatment and diagnostic purposes. Aliquots of these
samples and EDTA-treated blood from these patients were
used in this study after informed consent had been obtained.
Four patients were receiving anti-TNF-α therapy, three were
being treated with conventional therapy (nonsteroidal anti-
inflammatory drugs, steroids or disease-modifying anti-rheu-
matic drugs), and two patients were receiving no medication
at the time of synovial effusion although those had been
treated earlier (Table 1). Hence, all patients did not respond
sufficiently to the therapeutic treatment.
Purification of mononuclear cells and PMN from blood 
and SF
Purification of mononuclear cells (peripheral blood mononu-
clear cells; PBMC) and PMN from blood was performed as
described [21], with minor modifications. For sedimentation of
erythrocytes, 1 volume of EDTA-treated blood was incubated
with 1 volume of 3% dextran T500 (Roth, Karlsruhe, Germany)
in PBS (Biochrom, Berlin, Germany) for 20 minutes at 4°C.
The leucocyte-rich supernatant was centrifuged at 500 g for
10 minutes at 6°C in a Multifuge (Heraeus, Hanau, Germany).
The pellet was resuspended in PBS, overlaid on an isotonic
discontinous Percoll gradient (Amersham Biosciences,
Freiburg, Germany) with densities of 1.075 g/ml and 1.09 g/
ml and centrifuged at 750 g for 25 minutes at 6°C. PBMC or
PMN were collected at the relevant interphase and washed
twice with PBS. With the exception of dextran sedimentation,
the preparation of SF PMN was performed similarly. Cell-free
SF was obtained by centrifugation of SF at 750 g for 25 min-
utes and stored at -70°C in aliquots until use. PMN and mono-
nuclear cells were counted in SF from patients with RA. The
Table 1
Clinical data for patients with RA and healthy donors providing 
samples for microarray analysis
Subject Sex Age (years) Medication
RA patient
1 Female 55 NSAID (diclofenac)
2F e m a l e 5 3 N o n e
3 Female 72 Anti-TNF-α (adalimumab)
4F e m a l e N D N o n e
5 Female 44 Anti-TNF-α (infliximab)
6 Female 80 DMARDs (methotrexate and 
resochine)
7 Female 35 Anti-TNF-α (infliximab)
8M a l e 6 1 A n t i - T N F - α (infliximab)
9 Male 51 DMARD (methotrexate); steroid 
(cortisone)
Healthy donor
1F e m a l e 3 0 N o n e
2F e m a l e 2 6 N o n e
3F e m a l e 3 8 N o n e
4M a l e 2 7 N o n e
RA, rheumatoid arthritis; NSAID, nonsteroidal anti-inflammatory drug; 
DMARD, disease-modifying anti-rheumatic drug; ND, not determined.Available online http://arthritis-research.com/content/9/5/R94
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ratio between PMN and mononuclear cells was approximately
1:10.
Flow cytometry
The purity of PMN was routinely analyzed by flow cytometry
with FACSCalibur (BD Biosciences, Heidelberg, Germany). In
brief, to prevent nonspecific binding, 3 × 105 cells were prein-
cubated for 10 minutes with heat-inactivated (20 minutes,
56°C) human serum and were then incubated with a combina-
tion of fluorescein isothiocyanate-conjugated CD66b antibody
(Immunotech, Hamburg, Germany) and allophycocyanin
(APC)-conjugated CD14 antibody (Caltag, Hamburg, Ger-
many). After 30 minutes at 4°C, cells were washed twice with
PBS/1% FCS (Sigma, Deisenhofen, Germany) and kept on
ice until analysis. Data were analyzed with CellQuest software
(BD Biosciences), revealing a purity of 98 to 99% CD66b-
positive PMN with a contamination of less than 0.05% CD14-
positive and CD66b-negative cells. Analysis of PMN prepara-
tions of three donors with anti-CD56-APC (BD Biosciences),
anti-CD3-phycoerythrin (Caltag) and anti-CD19-APC (Caltag)
revealed 0.01 to 0.04% natural killer cells, 0.06 to 0.33% T
cells and up to 0.06% B cells. In addition, PMN preparations
were subjected to histochemistry (Diff-Quick staining; Dade
Behring, Düdingen, Switzerland) showing 1 to 3% eosinophils
in each preparation of blood PMN. Selected cell culture exper-
iments were performed with PMN preparations depleted of
eosinophils with anti-CD16 antibodies by means of magnetic-
activated cell sorting (Miltenyi Biotec, Bergisch Gladbach,
Germany) to exclude the possibility that contaminating eosi-
nophils accounted for CCL18 production. Notably, no eosi-
nophils were detectable in preparations of SF PMN.
Cell culture
For culturing PMN, RPMI 1640 containing L-glutamine and
sodium bicarbonate (Sigma) was supplemented with 5 mM
HEPES (Sigma), 100 IU/ml penicillin, 100 μg/ml streptomycin
(Sigma) and 10% FCS. For pretreatment of PMN with SF,
blood PMN from healthy donors were seeded in six-well-plates
(Corning Costar, Bodenheim, Germany) at a density of 5 ×
107 cells in 5 ml of culture medium or 2.5 ml of culture medium
plus 2.5 ml of SF from patients with RA. After 10 hours of incu-
bation, cells were washed twice. Pretreated blood PMN as
well as freshly isolated blood PMN from healthy donors or
blood and SF PMN from patients with RA were seeded in 24-
well plates (Greiner Bio-One GmbH, Frickenhausen, Ger-
many) at a density of 5 × 106 cells in 500 μl of culture medium
with and without 20 ng/ml IL-10 (Endogen, Eching, Germany),
10-7 M vitamin D3 (1,25-dihydroxycholecalciferol; Calbiochem,
Darmstadt, Germany) and different concentrations (10, 1, 0.5
and 0.25 ng/ml) of recombinant TNF-α (Biolegend, Eching,
Germany). In addition, for co-culture experiments, 5 × 105 EA-
hy.926 human endothelial cells (Department of Experimental
Pathology, St Bartholomew's and the Royal London School of
Medicine, London) were plated in 24-well plates in DMEM
with 4,500 mg/l glucose, L-glutamine, sodium bicarbonate
and pyridoxine hydrochloride (Sigma) supplemented with 100
IU/ml penicillin, 100 μg/ml streptomycin and 10% FCS. After
1 hour of incubation at 37°C, 5% CO2 and 95% humidity, 5 ×
105 PBMC or 5 × 106 blood PMN from healthy donors were
added to a final volume of 500 μl of DMEM/10% FCS. Addi-
tionally PMN and EA-hy.926 cells were cultured in Boyden
chambers, separated by a transwell membrane with a pore
size of 0.4 μm (Corning Costar). For control experiments,
blood PMN or EA-hy.926 cells were γ-irradiated (40 Gy),
washed twice after 24 hours of incubation and co-cultured
with vital EA-hy.926 cells or PMN, respectively. After 24 or 48
hours of incubation, cells and supernatants were prepared for
subsequent isolation of RNA or ELISA analysis.
RNA sample preparation
For microarray analysis and RT-PCR, total RNA was extracted
from PMN with RNeasy Mini Spin Columns (Qiagen, Hilden,
Germany) in accordance with the manufacturer's instructions.
From cell cultures, RNA was prepared with the acid-phenol
extraction procedure [22]. All RNA samples were digested
with DNAse (DNA-free™ Kit; Ambion, Huntingdon, UK). RNA
yields were determined spectrophotometrically by measuring
the absorbance at 260 and 280 nm. All RNA samples used for
microarray analysis were analyzed with an RNA 6000 Nano
Labchip (Agilent Technologies, Böblingen, Germany) for RNA
degradation. Only RNA preparations with no detectable deg-
radation were used for microarray analysis.
Microarray hybridization
Experiments were performed with the Lab-Arraytor®-60 inflam-
mation microarray (SIRS-Lab, Jena, Germany) comprising 800
probes (each measurement being made in triplicate) address-
ing 780 transcripts corresponding to inflammation as well as
20 control probes. The microarray data according to Minimal
Information about a Microarray Experiment (MIAME) guide-
lines were deposited in the database ArrayExpress [23] with
the accession number E-MEXP-994. RNA samples of SF PMN
from nine RA patients and of blood PMN from four healthy
donors (Table 1) were amplified with BD Atlas™ SMART™ Flu-
orescent Amplification Kit (BD Biosciences) in accordance
with the manufacturer's instructions. cDNAs were cleaned
with a Promega Wizard PCR clean-up Kit (Promega, Man-
nheim, Germany) and labeled by use of the Dyomics DY-648-
S-NHS/DY-548-S-NHS dye system (Dyomics, Jena, Ger-
many). Dyomics DY-648-S-NHS-labeled cDNA was cohybrid-
ized with DY-548-S-NHS-labeled cDNA obtained from the
same amount of total RNA isolated from the immature mono-
cytic cell line SigM5 obtained from the German Resource
Centre for Biological Material (DSMZ, Braunschweig,
Germany) and subjected to culture under standard conditions.
After incubation in a hybridization apparatus (HS 400; TECAN
Group Ltd, Männedorf, Switzerland), for 10 hours at 42°C in a
formamide-based hybridization buffer system, arrays were
washed in accordance with the manufacturer's instructions
and dried; hybridization signal intensities were measuredArthritis Research & Therapy    Vol 9 No 5    Auer et al.
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immediately with an array scanner (model Gene Pix 4000B;
Axon Instruments, Union City, CA, USA).
Microarray data preprocessing
Digital images resulting from post-hybridization array scanning
were quantified with GenePix Pro 4.0 software (Axon Instru-
ments). GenePix™ Analysis Software was used for spot detec-
tion and quantification and also for spot quality flagging.
Significantly regulated genes were determined by using a two-
sample permutation test. The threshold of significance for mul-
tiple comparisons was defined with calculating the corre-
sponding q value for each p value [24]. For normalization and
variance-stabilized transformation of raw signals the method of
Huber and colleagues [25] was used, in which the data were
transformed by an arcsinh function; for example, a transformed
ratio of ± 0.4 corresponds to approximately 1.5-fold change
(almost identical with the natural logarithm). Genes with mean
transformed ratios less than -1 and larger than +1 were signif-
icantly regulated. Genes were clustered with the Database for
Annotation, Visualization and Integrated Discovery (DAVID)
software [26].
Semiquantitative and quantitative RT-PCR
Changes in gene expression assessed by microarray analysis
were confirmed by semiquantitative and quantitative RT-PCR
for selected genes, namely CXCL10, CCL18, CCRL2 and
CXCR4. In brief, cDNA was synthesized from 0.5 μg of total
RNA by using 0.5 μg of oligo(dT) 16-mer primer (Thermo, Ulm,
Germany), 0.5 mM dNTP (Invitrogen, Karlsruhe, Germany) and
1 unit (U) of Omniscript reverse transcriptase (Qiagen) in a
final volume of 25 μl at 37°C for 60 minutes and at 93°C for 5
minutes. PCR was performed in a 25 μl reaction mixture con-
taining 2 μl of cDNA sample, 0.625 U of Taq polymerase (Qia-
gen), 0.2 mM dNTPs (Invitrogen) and sense and antisense
primers (each at 0.4 μM). Amplification was performed at
95°C for 2 minutes followed by 34 cycles with a denaturing
step at 94°C for 1 minute, an annealing step at 55°C for 50 s
and an extension step at 72°C for 90 s. A final extension step
was performed at 72°C for 7 minutes on a thermocycler
(Biozym, Hess. Oldendorf, Germany). Primers for CCRL2 (5'-
TGA CAA GTA TGA CGC CCA G-3' and 5'-ACC AGG ATA
AGC ACA ACC AG-3'), CCL18 (5'-CTC CTT GTC CTC
GTC TGC AC-3' and 5'-TCA GGC ATT CAG CTT CAG GT-
3'), CXCR4 [27], CXCL10 [28] and β-actin [29] were pur-
chased from MWG Biotech (Ebersberg, Germany). PCR sam-
ples were separated on 2% agarose gels (Roth), revealed by
ethidium bromide staining (Merck, Darmstadt, Germany) and
photographed on an ImageMaster VDS (Amersham
Biosciences).
Quantitative PCR was performed in a 20 μl reaction mixture
containing 2 μl of cDNA (diluted 1:5 in water), 1 U of Platinum-
Taq-Polymerase (Invitrogen), 0.5× SYBR-Green (Roche, Man-
nheim, Germany), 5% dimethylsulfoxide (Sigma), 0.5 mg/ml
bovine serum albumin (New England Biolabs, Frankfurt, Ger-
many), 0.25 mM dNTP (Amersham), 4 mM magnesium chlo-
ride (Invitrogen) and sense and antisense primers (each at 0.4
μM). Amplification was performed with a real-time light cycler
(Roche) at 95°C, 10 minutes, 20°C/s of preincubation fol-
lowed by 50 cycles of denaturing at 95°C, 15 s, 20°C/s,
annealing at 55°C (CCL18) and 56°C (HPRT), 10 s, 20°C/s
and extension at 72°C, 15 s, 20°C/s. The melting curve was
performed at 95°C, 0 s, 20°C/s followed by 65°C, 15 s, 20°C/
s and 95°C, 0 s, 0.1°C/s. Cooling was done at 40°C, 30 s,
20°C/s. CCL18 values were normalized with HPRT values and
are presented as relative gene expression ratios with the 2-ΔΔCt
method [30]. CCL18 primer (5'-GGG GGC TGG TTT CAG
AAT A-3' and 5'-CTC CTT GTC CTC GTC TGC AC-3') and
HPRT primer (5'-GAC TTT GCT TTC CTT GGT CA-3' and 5'-
GGC TTT GTA TTT TGC TTT TCC-3') for quantitative RT-
PCR were purchased from MWG Biotech. All primer
sequences correspond to sequences for human cDNAs
deposited in GenBank.
ELISA analysis
CCL18 and TNF-α levels in culture supernatants were quanti-
fied with human CCL18 and TNF-α ELISA (DuoSet® ELISA
Development System; R&D Systems, Wiesbaden-Nordens-
tadt, Germany) in accordance with the manufacturer's instruc-
tions. Substrate reagents A and B were from BD Biosciences.
The sensitivity of both assays was 5 pg/ml.
Statistical analysis
All experiments were performed at least three times. The val-
ues are expressed as means ± SEM. A Wilcoxon test was
used to assess the significance of differences between two
conditions. All p values are two-tailed, and p < 0.05 is consid-
ered significant. Statistical analysis was performed with the
software package provided by Prism 3.0®.
Results
Expression of CCL18 in SF PMN
RNA preparations were obtained from SF PMN from nine indi-
vidual patients with RA and from peripheral blood PMN from
four healthy donors (Table 1) and subjected to microarray
analysis. Results summarized in Figure 1 show a highly upreg-
ulated expression of CCL3 and CCL18 mRNAs, a downregu-
lation of CCL21 mRNA (Figure 1a) and an upregulation of
CXCL8 and CXCL10 mRNAs (Figure 1b) in SF PMN from
each patient in comparison with blood PMN from healthy
donors. As revealed by flow cytometry with CD66b antibodies,
SF PMN form one representative RA patient prepared for
microarray experiments were of 99% purity. Natural killer cells,
T cells, B cells and monocytes/macrophages were not detect-
able (Figure 1c). To validate the microarray data,
semiquantitative RT-PCR was performed with the same RNAs
as used in the microarray analysis of four randomly selected
RA patients (namely nos 1, 2, 7 and 8) and one of the healthy
donors (namely no. 2). As shown in Figure 2a, mRNA expres-
sion for two selected chemokines, CCL18 and CXCL10, wasAvailable online http://arthritis-research.com/content/9/5/R94
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readily detectable in SF PMN but remained undetectable in
peripheral blood PMN from the healthy donor. In addition,
quantitative RT-PCR revealed changes in CCL18 expression
in SF PMN from RA patients (n = 9; Figure 2b) similar to those
observed with microarray analysis. These data indicate that the
microarray analysis reflects a true transcriptional profile of
chemokines in SF PMN. Differences observed in CCL18
mRNA expression levels in SF PMN between individual RA
patients did not relate to the actual therapeutic treatment (p =
0.2612, none versus conventional therapy; p = 0.3798, none
versus anti-TNF therapy) as determined by quantitative RT-
PCR (data not shown). Notably, no significant levels of CCL18
mRNA were detectable in blood PMN form RA patients (n =
9; Figure 2b), suggesting that CCL18 gene expression in SF
PMN occurs as a result of the recruitment of PMN into the
inflammatory milieu of the joint.
Differential expression of chemokine receptors in SF 
PMN
To estimate changes in the responsiveness of SF PMN to
chemokine ligands, expression levels of chemokine receptor
mRNAs were determined by microarray analysis as described
Figure 1
Microarray analysis of chemokine gene expression in synovial fluid polymorphonuclear neutrophils Microarray analysis of chemokine gene expression in synovial fluid polymorphonuclear neutrophils. RNA of SF synovial fluid polymorphonuclear neu-
trophils (SF PMN) from nine patients with rheumatoid arthritis (RA) was analyzed for the expression of CC chemokines (a) and CXC, C and CX3C 
chemokines (b). Data obtained by Gene Pix™ Analysis Software were normalized, transformed and denoted as x-fold regulation versus the expres-
sion of blood PMN from healthy donors. Bars represent the median expression between nine RNA samples. Genes with median expression ratios 
less than -1 or more than +1 were significantly regulated. (c) SF PMN from one representative patient with RA (no. 2) were subjected to flow cytom-
etry with fluorescein isothiocyanate-conjugated anti-CD66b, allophycocyanin (APC)-conjugated anti-CD56, phycoerythrin (PE)-conjugated anti-
CD3, anti-CD19-APC and anti-CD14-APC antibodies.Arthritis Research & Therapy    Vol 9 No 5    Auer et al.
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above. Results in Figure 3a show an upregulation of CXCR4,
CCRL2 and CCR5 in SF PMN from patients with RA in com-
parison with blood PMN from healthy donors. For many other
receptors, particularly the neutrophil receptors CXCR1 and
CXCR2, mRNA levels were downregulated. When RNA from
SF PMN obtained from RA patient nos 1, 2, 7 and 8 and
healthy donor no. 2 was used, semiquantitative RT-PCR (Fig-
ure 3b) revealed an upregulation of two selected chemokine
receptors, CCRL2 and CXCR4, in SF PMN, thereby confirm-
ing the results of the microarray analysis. These data therefore
indicate that chemokine responsiveness of SF PMN is regu-
lated, at least in part, through the differential regulation of
chemokine receptor expression.
Induction of CCL18 protein synthesis in SF PMN
To determine whether SF PMN might contribute to CCL18
protein levels in inflamed joints, supernatants of cultured SF
PMN from patients with RA were subjected to ELISA analysis.
The results (Figure 4a) showed no spontaneous release of
CCL18 by SF PMN. However, CCL18 could be induced by
stimulation of SF PMN with IL-10; indeed, IL-10 in combina-
tion with vitamin D3 even enhanced CCL18 release. In con-
trast, SF PMN from patients with RA did not release CCL18 in
response to TNF-α. In addition, the effect of IL-10 in combina-
tion with TNF-α was not significantly different from that of IL-
10 alone, suggesting that TNF-α may not be involved in
CCL18 protein synthesis. Because IL-10 is frequently found in
SF from patients with RA [31], PMN recruited into joints are
likely to contribute to the local production of CCL18.
Furthermore, because SF PMN from patients with RA were
shown to express CCL18 mRNA in the absence of detectable
CCL18 protein, it is evident from these data that the synthesis
of CCL18 protein requires a secondary signal.
TNF-α induces CCL18 mRNA in the absence of CCL18 
protein in blood PMN
To identify regulatory mechanisms involved in CCL18 expres-
sion, a putative role of TNF-α as a sensitizing agent was inves-
tigated in cultures of blood PMN from healthy donors. The
results shown in Figure 4b confirmed TNF-α as a potent
inducer of CCL18 mRNA expression. However, ELISA analy-
sis of CCL18 levels in supernatants of the same cell cultures
revealed no detectable CCL18 protein after 24 or 48 hours of
incubation (data not shown), indicating that TNF-α induced
CCL18 mRNA expression in the absence of protein synthesis.
Interestingly, as shown in Figure 4a, neither blood PMN from
healthy donors nor blood PMN from patients with RA released
significant amounts of CCL18 in response to IL-10 alone or to
a combination of IL-10 and TNF-α, suggesting that TNF-α
alone may not be sufficient to prime PMN for CCL18 synthe-
sis. This conclusion is supported by data showing that CCL18
production could be induced by stimulating PMN with IL-10
and vitamin D3 in the absence of exogenous TNF-α (Figure
4a). To investigate whether the difference between SF PMN
and blood PMN in their responsiveness to IL-10 was due to
soluble factors present in SF, blood PMN from healthy donors
were pretreated with SF from patients with RA and subse-
quently stimulated with IL-10 alone or in combination with vita-
min D3. The results in Figure 4c show that preincubation with
SF supported induction by IL-10 alone. Incubation with both
IL-10 and vitamin D3 produced the release of even more
CCL18 by PMN preincubated with SF.
Endothelial cells induce CCL18 protein in PMN
To determine whether extravasation might have a role in the
induction of CCL18 release, PMN and PBMC from healthy
donors were co-cultured with the endothelial cell line EA-
hy.926. Results in Figure 5a revealed high levels of CCL18 in
culture supernatants of PMN or PBMC co-cultured with
Figure 2
Semiquantitative and quantitative RT-PCR analysis of CCL18 mRNA in  polymorphonuclear neutrophils Semiquantitative and quantitative RT-PCR analysis of CCL18 mRNA in 
polymorphonuclear neutrophils. (a) Total RNA from synovial fluid poly-
morphonuclear neutrophils (SF PMN) of rheumatoid arthritis (RA) 
patients nos 1, 2, 7 and 8 and from blood PMN from healthy donor no. 
2 was amplified by semiquantitative RT-PCR with primers for CCL18, 
CXCL10 and actin and subjected to agarose gel electrophoresis. PCR 
was repeated twice. (b) Total RNA from blood and SF PMN from 
patients with RA (n = 9) and from blood PMN from healthy donors (n = 
4) were subjected to quantitative RT-PCR with primers for CCL18 and 
HPRT. CCL18 transcript levels are presented as relative expression 
ratios. Bars represent median expression between RNA samples.Available online http://arthritis-research.com/content/9/5/R94
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endothelial cells, whereas no release of CCL18 was observed
when PMN and EA-hy.926 cells were incubated separately
from each other in Boyden chambers. Similar levels of CCL18
were released into supernatant of RA blood or SF PMN co-cul-
tured with endothelial cells (data not shown). The data there-
fore indicate that cell–cell contact is crucial for the induction
of CCL18. Release of CCL18 was induced by endogenous
TNF-α, as revealed by blocking experiments with excess anti-
TNF-α antibodies (Figure 5b). In controls, stimulation of EA-
hy.926 cells with TNF-α was found to induce neither the
release of CCL18 (Figure 5b) nor the expression of CCL18
mRNA (Figure 5c), suggesting that CCL18 derives from PMN.
To determine the origin of TNF-α in co-cultures, either PMN or
EA-hy.926 cells were pretreated with γ-radiation and then
incubated with the viable cellular counterpart. As shown in Fig-
ure 5d, irradiation of PMN on their own abolished the produc-
tion of TNF-α in co-culture with EA-hy.926 cells, indicating that
PMN are the predominant source of TNF-α in co-cultures. The
results therefore suggest that cell contact with endothelial
cells induces TNF-α in PMN, which in turn induces CCL18
production by PMN in an autocrine manner.
Discussion
This study describes PMN, and particularly SF PMN from
patients with RA, as a novel cellular source of the chemokine
CCL18. As judged by the immunostaining of SF PMN with
anti-CD66b, nongranulocytic cells constituted less than 1% of
the PMN preparations. Flow cytometry confirmed the low fre-
quency (0.05%) of CD14-positive monoctyes/macrophages
in isolated PMN populations, suggesting that contaminating
cells are unlikely to have a significant role in the chemokine
profile determined by microarray analysis. In addition, data are
presented to show that the production of CCL18 by PMN is
differentially regulated at the levels of mRNA expression and
protein synthesis. CCL18 was originally described to be con-
stitutively expressed in lung and lymphoid tissue [32]. At the
Figure 3
Microarray analysis of chemokine receptor gene expression in synovial fluid polymorphonuclear neutrophils Microarray analysis of chemokine receptor gene expression in synovial fluid polymorphonuclear neutrophils. (a) RNA of synovial fluid polymorphonu-
clear neutrophils (SF PMN) from nine patients with rheumatoid arthritis (RA) was analyzed for chemokine receptor expression. Data obtained by 
Gene Pix™ Analysis Software were normalized, transformed and denoted as x-fold regulation versus expression of blood PMN from healthy donors. 
Bars represent median expression between nine RNA samples. Genes with median expression ratios less than -1 or more than +1 were significantly 
regulated. (b) Total RNA from SF PMN from RA patients nos 1, 2, 7 and 8 and from blood PMN from healthy donor no. 2 was amplified by semiquan-
titative RT-PCR with primers for CCRL2, CXCR4 and actin and subjected to agarose gel electrophoresis. PCR was repeated twice.
(a)
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cellular level CCL18 production seems to be restricted to den-
dritric cells and monocytes/macrophages [18,19]. T helper
cell type 2-related cytokines, including IL-4, IL-10 and IL-13,
were found to induce or enhance CCL18 expression, whereas
the T helper type 1-derived interferon-γ suppressed CCL18
mRNA expression [17]. There is also evidence for a superan-
tigen-induced CCL18 production by PBMC [19].
It is shown here that CCL18 mRNA expression is induced in
PMN by TNF-α in the absence of detectable amounts of
CCL18 protein, suggesting that TNF-α provides an early sig-
nal for CCL18 transcription. Consistent with these cell culture
observations, steady-state levels of CCL18 mRNA were read-
ily found in SF PMN from patients with RA in the absence of
detectable cell-associated CCL18. Its synthesis, however,
was inducible on incubation of SF PMN with IL-10. Previous
studies showed that TNF-α is able to prime PMN for subse-
quent downstream events [33]. Hence it is reasonable to con-
clude that CCL18 production by PMN requires two
independent signals, one for mRNA expression, provided by
TNF-α, and the other for protein synthesis, mediated by IL-10;
these two cytokines are readily available in SF [31]. In DC cul-
tures, differential regulation of CCL18 mRNA and protein
expression has been attributed to changes in maturation
[34,35]. It is unclear whether additional maturation also
accounts for the differential regulation of CCL18 in PMN,
because this cell type is considered to be terminally differenti-
ated. However, Iking-Konert and colleagues [36] suggested
Figure 4
Induction of CCL18 mRNA and protein in synovial fluid and blood polymorphonuclear neutrophils Induction of CCL18 mRNA and protein in synovial fluid and blood polymorphonuclear neutrophils. (a) Synovial fluid polymorphonuclear neutrophils 
(SF PMN) of patients with rheumatoid arthritis (RA) and blood PMN from healthy donors and patients with RA were incubated with 20 ng/ml IL-10, 
10-7 M vitamin D3 and 10 ng/ml TNF-α for 48 hours. Levels of CCL18 in the supernatant were determined by ELISA. Data represent the geometric 
mean ± SEM for three independent experiments performed in duplicate. (b) PMN from healthy donors were incubated for 24 hours with various 
amounts of recombinant TNF-α. Total RNA was amplified by semiquantitative RT-PCR with primers for CCL18 and actin and subjected to agarose 
gel electrophoresis. This result is representative of three independent experiments with PMN from three different donors. (c) Blood PMN from 
healthy donors were incubated in the presence or absence of SF from patients with RA for 10 hours, then washed twice and incubated for a further 
48 hours with 20 ng/ml IL-10 and 10-7 M vitamin D3. Data represent the geometric mean ± SEM for three independent experiments performed in 
duplicate.Available online http://arthritis-research.com/content/9/5/R94
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that SF PMN can further differentiate into a dendritic-like phe-
notype. Another speculative explanation for the regulation of
CCL18 synthesis in PMN might involve microRNAs [37].
Because TNF-α-dependent production of CCL18 by PMN
was inducible by means of cell–cell contact with endothelial
cells, IL-10 may not be the only inducer for CCL18 synthesis.
It has previously been shown that recognition of β2-integrin/
ICAM-1 on fibroblast-like synoviocytes induced MIP-1α
expression in SF PMN [38]. Whether a similar ICAM-1-related
mechanism accounts for the endothelial cell-mediated induc-
tion of CCL18 in PMN is unknown.
IL-10 alone was unable to induce CCL18 in blood PMN, and
its release was not enhanced by stimulating PMN with IL-10 in
combination with TNF-α. The apparent difference in IL-10
responsiveness between SF PMN and blood PMN from
patients with RA may result from different expression patterns
Figure 5
CCL18 induction of polymorphonuclear neutrophils co-cultured with endothelial cells requires cell–cell contact and TNF-α CCL18 induction of polymorphonuclear neutrophils co-cultured with endothelial cells requires cell–cell contact and TNF-α. (a) CCL18 levels were 
measured by ELISA in culture supernatants of 5 × 105 peripheral blood mononuclear cells, 5 × 106 polymorphonuclear neutrophils (PMN) or 5 × 
105 EA-hy.926 cells alone or after co-culture with EA-hy.926 cells after incubation for 48 hours. Direct cell–cell contact of PMN and EA-hy.926 cells 
was prevented by Boyden chambers (bc) as indicated. Data represent the geometric mean ± SEM of CCL18 measured in four independent experi-
ments performed in duplicate. (b) CCL18 levels were measured in culture supernatants of PMN and EA-hy.926 cells alone or after co-culture of 
both cell types after incubation for 48 hours. Cultures were supplemented with anti-TNF-α antibodies (infliximab; 50 μg/ml) or 10 ng/ml TNF-α as 
indicated. Data represent the geometric mean ± SEM of three independent experiments performed in duplicate. (c) RNA was prepared from PMN 
and EA-hy.926 cells alone or after co-culture of both cell types after incubation for 24 hours. Cultures were supplemented with TNF-α (10 ng/ml) as 
indicated. RNA samples were amplified by semiquantitative RT-PCR with primers for CCL18 and actin and subjected to gel electrophoresis. This 
result is representative of three independent experiments with PMN from three different donors. (d) TNF-α levels were measured by ELISA in culture 
supernatants of PMN and EA-hy.926 cells alone and in co-cultures of PMN and EA-hy.926 cells before or after γ-irradiation (40 Gy) of one of these 
cell types. The irradiated cell type is marked with an asterisk. Data represent the geometric mean ± SEM for three independent experiments per-
formed in duplicate.Arthritis Research & Therapy    Vol 9 No 5    Auer et al.
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of the IL-10 receptors (IL-10R). It was shown that circulating
PMN express high levels of the IL-10R2 and low levels of IL-
10R1 [39]. Increasing IL-10R1 by stimulation with lipopoly-
saccharide coincided with an increased responsiveness of
PMN to IL-10. The increased responsiveness in SF PMN may
be induced by soluble factors present in SF, because preincu-
bation of blood PMN with SF supported the induction of
CCL18 by IL-10 alone. In this context, CCL18 production was
synergistically enhanced when PMN were stimulated with IL-
10 in combination with vitamin D3. These findings suggest that
the high CCL18 levels in SF from RA patients [19] may be
induced synergistically, as previously shown for monocytes
cultured with IL-10 and SF from patients with RA [35]. The uni-
dentified stimulating activity in SF [35] may be attributed to
vitamin D3, because SF macrophages were shown to be able
to produce vitamin D3 in cell culture experiments [40]. As IL-
10 and vitamin D3 are known to have anti-inflammatory proper-
ties [41,42], the release of CCL18 induced by these media-
tors might contribute to a suppression of joint inflammation.
CCL18 has already been recognized in tissues and joints of
patients with RA. In particular, high levels of CCL18 were
measured in SF, and immunostaining of tissue sections
revealed CCL18 production in perivascular regions of the syn-
ovia in CD68-positive monocytes/macrophages [19]. Further-
more, CCL18 mRNA and protein were found in DCs,
generated in vitro from monocytes of RA patients [43], imply-
ing that high levels of CCL18 in SF originate from macro-
phages as well as DCs. The contribution of PMN to the
accumulation of CCL18 in SF is difficult to judge because the
cells have a low production rate for cellular mediators. How-
ever, because PMN are the majority of cells recruited into SF,
the large number of PMN may compensate for their low
production rate at the cellular level [44]. PMN may therefore
be considered a cellular source of CCL18, contributing at
least partly to the levels of CCL18 found in diseased joints.
Microarray analysis was performed to compare CCL18 mRNA
expression in SF PMN from patients with RA with expression
levels of other chemokines. The results show a characteristic
profile of highly regulated chemokine mRNAs that form a
group of four upregulated chemokines, namely CCL18, CCL3,
CXCL8 and CXCL10, and one downregulated chemokine,
namely CCL21. It is therefore unlikely that SF PMN favor the
formation of ectopic germinal centers, in which increased
levels of CCL21 were detected [45]. In contrast with the tran-
scriptional program of terminal granulocytic differentiation
[46], chemokines in SF PMN from patients with RA were not
upregulated in parallel with their receptors. With the exception
of CXCR4, CCRL2 and CCR5 mRNAs, most chemokine
receptors were downregulated in SF PMN, supporting the
notion of a differential modulation of chemokine receptors and
their ligands during chronic inflammation. These findings sug-
gest that SF PMN from patients with RA develop into a stage
of unresponsiveness through the downregulation of chemok-
ine receptors. Possible mechanisms accounting for the sup-
pression of chemokine responsiveness may include ligand-
induced receptor internalization and TNF-α-mediated proteo-
lytic degradation of chemokine receptors [47]. However, it is
also possible that some of the SF PMN with low levels of
CXCR1, for example, develop into the recently described
long-lived PMN with the capability of migrating across the
endothelium in a retrograde direction [48]. In contrast, large
numbers of CCR5 molecules on PMN have been attributed to
a sequestration of chemokines, which may help to resolve the
local inflammation [49]. Upregulation of CCR5 mRNA in SF
PMN may therefore contribute to a regulation of the local
chemokine response in diseased joints. The role of CCRL2 on
SF PMN remains obscure, because no ligand has yet been
identified [50].
Microarray analysis of blood PMN from patients with X-linked
chronic granulomatous disease revealed increased mRNA lev-
els for only two chemokines, namely CXCL8 and CXCL1 [51].
When compared with the chemokine expression profile in SF
PMN from patients with RA, the data indicate a disease-spe-
cific expression of chemokines in PMN. This conclusion is sup-
ported, at least in part, by the results of Sukumaran and
colleagues [52], who reported the upregulated expression of
chemokine genes encoding CXCL1, CXCL2, CXCL3,
CXCL8, CCL3, CCL4 and CCL20 after infection of PMN with
Anaplasma phagocytophilum. However, no mRNA expression
was observed for CCL18 and CXCL10 in PMN infected with
A. phagocytophilum.
Conclusion
This is the first study showing that SF PMN from patients with
RA is a cellular source of CCL18. Its production by PMN
seems to be tightly regulated at the levels of mRNA expression
and protein synthesis. SF PMN from patients with RA exhibit a
characteristic chemokine expression pattern resembling the
upregulation of CCL3, CCL18, CXCL8 and CXCL10 mRNAs
and the downregulation of CCL21 mRNA. Blockade of
CCL18 expression by anti-TNF-α antibodies identifies CCL18
as an additional target for anti-TNF-α therapy in patients with
RA.
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